AssetMark’s Audentes Therapeutics BOLD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
– Sell
-35
Closed -$2K – 1605
2019
Q4
$2K Hold
35
– – ﹤0.01% 1282
2019
Q3
$1K Buy
+35
New +$1.2K ﹤0.01% 1298
2018
Q1
– Sell
-21
Closed -$1K – 2191
2017
Q4
$1K Buy
+21
New +$577 ﹤0.01% 1800

AssetMark's BOLD Position: Q1 2020 in Review

AssetMark sold out of Audentes Therapeutics (BOLD) in Q1 2020, closing a stake of 35 shares — an estimated $2K sold.

AssetMark first reported a position in BOLD in Q4 2017 and held it in 3 quarters. The position peaked at $2K in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.

  • AssetMark reported no remaining Audentes Therapeutics position as of Q1 2020 after selling out during the quarter.
  • AssetMark sold 35 Audentes Therapeutics shares in Q1 2020, an estimated $2K.
  • AssetMark first reported a position in Audentes Therapeutics in Q4 2017 and held it in 3 quarters.
  • AssetMark's Audentes Therapeutics position peaked at $2K in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Audentes Therapeutics as of Q1 2020.

Based on AssetMark's 13F filing for Q1 2020, filed 12 May 2020.